Traws Pharma, Inc. (TRAW) Stock Score, Valuation & Financial Research
Traws Pharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 61/100.
Quick answer for TRAW
Traws Pharma, Inc. currently has a Wall Street Score of 61/100. The stored market price is $0.56. Its financial score is 22/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What Traws Pharma, Inc. does
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future wo
TRAW financial snapshot
- Wall Street Score:
- 61/100
- Current price:
- $0.56
- Market capitalization:
- $8.6M
- Revenue:
- $2.8M
- Net income:
- $-23.9M
- Free cash flow:
- $-20.8M
- Cash:
- $3.1M
- Total debt:
- $0
- EPS:
- 0.83
- P/E ratio:
- 0.7x
- Financial score:
- 22/100
- Valuation score:
- 100/100
- Revenue score:
- 26/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-20.8M, showing cash burn in the current stored period.
- The balance sheet shows $3.1M of cash versus $0 of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TRAW
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.